Rosetta Genomic Announces Research Demonstrates Power of miRview mets to Identify Tissue of Origin in Carcinoma of Unknown Primary

Rosetta Genomics, Ltd. ROSG announces that results of a joint study with researchers at the University of Texas, M. D. Anderson Cancer Center show that Rosetta Genomics' miRview™ mets is a powerful tool to identify Tissue of Origin in Carcinoma of Unknown Primary patients. The study, entitled "microRNA-based diagnosis of Carcinoma of Unknown Primary," was published online April 29, 2011, and is set to appear in the print edition of Clinical Cancer Research.